Norges Bank’s CytomX Therapeutics CTMX Stock Holding History

Norges Bank’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-265,000	Closed	-$1.76M	–	2123
2020 Q3	$1.76M	Buy	+265,000	New	+$1.97M	﹤0.01%	1977

Other funds holding CTMX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank's CTMX Position: Q4 2020 in Review

Norges Bank sold out of CytomX Therapeutics (CTMX) in Q4 2020, closing a stake of 265,000 shares — an estimated $1.76M sold.

Norges Bank first reported a position in CTMX in Q3 2020 and held it in 1 quarter. The position peaked at $1.76M in Q3 2020. 126 funds tracked by Wall St. Rank hold CTMX as of Q4 2020.

Norges Bank reported no remaining CytomX Therapeutics position as of Q4 2020 after selling out during the quarter.
Norges Bank sold 265,000 CytomX Therapeutics shares in Q4 2020, an estimated $1.76M.
Norges Bank first reported a position in CytomX Therapeutics in Q3 2020 and held it in 1 quarter.
Norges Bank's CytomX Therapeutics position peaked at $1.76M in Q3 2020.
126 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2020.

Based on Norges Bank's 13F filing for Q4 2020, filed 10 Feb 2021.